Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:alsoKnownAs |
gptkb:Favipiravir
|
| gptkbp:approvedBy |
gptkb:Japan
|
| gptkbp:ATCCode |
J05AX27
|
| gptkbp:CASNumber |
259793-96-9
|
| gptkbp:category |
antiviral drug
pyrazinecarboxamide derivative |
| gptkbp:chemicalFormula |
C5H4FN3O2
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Toyama_Chemical
|
| gptkbp:discoveredIn |
2002
|
| https://www.w3.org/2000/01/rdf-schema#label |
T-705
|
| gptkbp:legalStatus |
prescription only (Japan)
|
| gptkbp:mechanismOfAction |
inhibits RNA-dependent RNA polymerase
|
| gptkbp:molecularWeight |
157.10 g/mol
|
| gptkbp:patent |
gptkb:Fujifilm_Holdings
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
teratogenicity
hyperuricemia |
| gptkbp:usedFor |
treatment of influenza
treatment of COVID-19 (investigational) |
| gptkbp:bfsParent |
gptkb:Favipiravir
|
| gptkbp:bfsLayer |
7
|